Sanofi Licenses Biomunex Pharmaceuticals’ BiXAb Technology to Develop Bi- and Multi-Specific Antibodies
Sanofi Licenses Biomunex Pharmaceuticals’ BiXAb Technology to Develop Bi- and Multi-Specific Antibodies
Shots:
- Biomunex to receive upfronts and milestones from Sanofi. Sanofi to get rights to access Biomunex’s BiXAb technology for the development of bi- and multi-specific antibody therapies and will also be responsible for its research and global commercialization
- The focus of the agreement is to utilize Biomunex’s platform to develop immunotherapies for multiple solid tumors including head-and-neck, gastric and pancreatic cancers
- Biomunex’ Plug-and-Play BiXAb is biospecific antibody platform involved in the development of bi- and multi-specific antibodies in multiple therapeutic areas including immune-mediated inflammatory and infectious diseases
Click here to read full press release/ article | Ref: Biomunex Phatmaceuticals| Image: Mab Design